The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | The RADAR trial: response-adapted therapy following autoSCT in patients with newly diagnosed myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, provides insight into the RADAR trial (ISRCTN46841867), a trial investigating risk and response-adapted therapy following autologous stem cell transplantation (autoSCT) in transplant-eligible patients with newly diagnosed multiple myeloma (MM). The study is due to complete enrollment in late 2025 and will aim to assess the outcomes with different treatment regimens in two distinct clinical groups – high-risk patients and those patients who are measurable residual disease (MRD)-positive after transplant. Dr Ramasamy believes that the findings of this trial will inform clinical practice in the near future. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The RADAR trial is a crucial, newly diagnosed, transplant-eligible myeloma trial. We are due to complete enrollment by the end of this year in 2025, and this is 1,400 patients. There are some outputs that are going to come out this year that I’m excited about.
The first is high-risk myeloma patients. The high-risk definition of myeloma continues to change because our treatments are also changing...
The RADAR trial is a crucial, newly diagnosed, transplant-eligible myeloma trial. We are due to complete enrollment by the end of this year in 2025, and this is 1,400 patients. There are some outputs that are going to come out this year that I’m excited about.
The first is high-risk myeloma patients. The high-risk definition of myeloma continues to change because our treatments are also changing. The high-risk nature is those patients who respond very poorly. So the high-risk definition we used in RADAR many years ago is the definition that’s currently being used by the International Myeloma Working Group.
So within this trial, we have the ability to talk about how are these patients doing with a treatment combination with almost a quadruplet therapy induction, quadruplet therapy consolidation following a transplant, and a doublet maintenance. If this shows that patients continue to derive significant benefit, then we’ll have to think about whether bringing in BCMA-targeted agents, how could it further augment for high-risk patients?
The second area of clinical output for us in the RADAR trial is there are patients who are MRD-positive after transplant. The outcomes of these patients are poorer in comparison to patients who are MRD negative. In the trial, we’re testing whether just giving lenalidomide or whether you give consolidation and then give doublet maintenance is a better way of converting to MRD negativity, which will then subsequently improve their clinical outcomes. And we’ll have results of this part of the RADAR trial this year.
So really excited to be able to contribute to the knowledge of newly diagnosed transplant-eligible myeloma, and this will shape some of our clinical practice in the not so distant future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
GSK: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Sanofi: Consultancy, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau; Adaptive Biotech: Consultancy, Speakers Bureau; Johnson and Johnson: Consultancy, Speakers Bureau; Menarini Stemline: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Recordati rare Disease: Consultancy, Speakers Bureau.
